Rates of Emergence of HIV Drug Resistance in Resource-Limited Settings: A Systematic Review
Tóm tắt
The increasing availability of antiretroviral therapy (ART) has improved survival and quality of life for many infected with HIV, but can also engender drug resistance. This review summarizes the available information on drug resistance in adults in resource-limited settings.
The online databases PubMed and Google Scholar, pertinent conference abstracts and references from relevant articles were searched for publications available before November 2011. Data collected after ART rollout were reviewed.
A total of 7 studies fulfilled the criteria for the analysis of acquired drug resistance and 22 fulfilled the criteria for the analysis of transmitted drug resistance (TDR). Acquired resistance was detected in 7.2% of patients on ART for 6–11 months, 11.1% at 12–23 months, 15.0% at 24-35 months, and 20.7% at ≥36 months. Multi-class drug resistance increased steadily with time on ART. The overall rate of TDR in all resource-limited countries studied was 6.6% (469/7,063). Patients in countries in which ART had been available for ≥5 years were 1.7x more likely to have TDR than those living in a country where ART had been available for <5 years ( P<0.001). The reported prevalence of TDR was 5.7% (233/4,069) in Africa, 7.6% (160/2,094) in Asia and 8.4% (76/900) in Brazil.
The emergence of drug resistance following access to ART in resource-limited settings resembles what was seen in resource-rich countries and highlights the need for virological monitoring for drug failure, drug resistance testing and alternative drug regimens that have proven beneficial in these resource-rich settings.
Từ khóa
Tài liệu tham khảo
Joint United Nations Programme on HIV/AIDS. UNAIDS World AIDS Day Report 2011. (Accessed 7 December 2012.) Available from http://www.unaids.org/en/media/unaids/contentassets/documents/unaidspublication/2011/jc2216_worldaidsday_report_2011_en.pdf.
Johnson V.A., 2010, Top HIV Med, 18, 156
Stanford University HIV Drug Resistance Database. (Accessed 12 April 2011.) Available from http://hivdb.stanford.edu/index.html.
Agence Nationale de Recherche sur le SIDA. ANRS HIV-1 genotypic drug resistance interpretation's algorithims. (Updated July 2009. Accessed 12 April 2011.) Available from http://www.hivfrenchresistance.org/archives.html.
International Treatment Preparedness Coalition. Missing the target #5: improving AIDS drug access and advancing health care for all. (Updated December 2007. Accessed 12 August 2011.) Available from http://aidsdatahub.org/dmdocuments/2007_Improving_AIDS_Drug_Access_and_Advancing_Health_Care_for_All.pdf.pdf.
United Nations. Composition of macro geographical (continental) regions, geographical sub-regions, and selected economic and other groupings. (Updated 2011. Accessed 10 April 2011.) Available from http://millenniumindicators.un.org/unsd/methods/m49/m49regin.htm#africa.
Monleau M., 2011, Journal of AIDS and HIV Research Vol, 3, 114
Yang C., Nguyen B.D., Bile E., Marum L., Wagar N., Nkengasong J. Global surveillance of transmitted hiv-1 drug resistance in PEPFAR-supported countries using a broadly sensitive genotyping assay.18th Conference on Retroviruses and Opportunistic Infections.27 February–2 March 2011, Boston, MA, USA. Abstract 619.
Ndembi N., Hamers R., Sigaloff K. Increasing primary HIV-1 drug resistance among recently infected persons in Uganda, East Africa.18th Conference on Retroviruses and Opportunistic Infections.27 February–2 March 2011, Boston, MA, USA. Abstract 621.
Soares C., Vergara T., Sucupira M.C. Prevalence of transmitted HIV-1 antiretroviral resistance among patients initiating ART in Brazil: a surveillance using dried blood spots.18th Conference on Retroviruses and Opportunistic Infections.27 February–2 March 2011, Boston, MA, USA. Abstract 624.
Vu T., Le T., Torok E. HIV-1 drug resistance in antiretroviral-naïve patients with HIV-associated tuberculous meningitis in Ho Chi Minh City, Vietnam.18th Conference on Retroviruses and Opportunistic Infections.27 February–2 March 2011, Boston, MA, USA. Abstract 625.
Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. Department of Health and Human Services. (Updated 27 March 2012. Accessed 12 September 2012.) Available from http://aidsinfo.nih.gov/ContentFiles/AdultandAdolescentGL.pdf.
World Health Organization. Antiretroviral therapy for HIV infection in adults and adolescents: recommendations for a public health approach. 2010 revision. (Updated 2010. Accessed 2 August 2011.) Available from http://whqlibdoc.who.int/publications/2010/9789241599764_eng.pdf.